A New Minimal-invasive Brain Tissue Probe Applying Near Infrared Spectroscopy (NCT01801306) | Clinical Trial Compass
CompletedNot Applicable
A New Minimal-invasive Brain Tissue Probe Applying Near Infrared Spectroscopy
Germany3 participantsStarted 2013-03
Plain-language summary
To assess the feasibility of a new brain tissue probe for multi-parameter neuromonitoring (NeMo Probe) and the accuracy of measurement values.
To demonstrate the ability of the NeMo probe to detect changes in cerebral hemodynamics and oxygenation during cerebrovascular events monitored with established methods including brain tissue oxygenation tension and microdialysis
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Males and females aged 18-75 years (inclusive)
* Patients with high-grade subarachnoid hemorrhage (WFNS 4-5)
* Decreased level of consciousness with the need for intracranial pressure monitoring
* Successful exclusion of the ruptured aneurysm with clipping or coiling
* Women of childbearing potential must have a negative serum pregnancy test
* Written informed consent obtained by a legal representative
Exclusion Criteria:
* Significant kidney and/or liver disease
* Any severe unstable concomitant condition or disease (e.g. cancer, coronary disease) or chronic condition (e.g. psychiatric disorder, chronic obstructive pulmonary disease Grade II, chronic heart failure \> NYHA II)
* Cerebrospinal fluid infection or signs of meningoencephalitis
* Acute respiratory distress syndrome (ARDS), pulmonary edema
* Preexisting coagulation disorder
* Patients with current alcohol or drug abusus or dependence
* Patients with a history of hypersensitivity against indocyanine green or sodium iodine
* Patients with thyroid disease causing hyperthyroidism
* Breast-feeding women
* Patients committed to an institution based on official directive or court order
What they're measuring
1
To assess the feasibility of the neuromonitoring system and accuracy of the measurement values